APTEVO THERAPEUTICS INC.
2401 4th Avenue, Suite 1050
Seattle, WA 98121
December 17, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Jeffrey Gabor
Re: Aptevo Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-251318
Dear Mr. Gabor:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-251318) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:05 p.m., Eastern Time, on December 18, 2020, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Morgan, Lewis & Bockius LLP, by calling Sean M. Donahue at (202) 538-3557.
[Remainder of page intentionally left blank]
Very truly yours,
Aptevo Therapeutics Inc.
By: /s/ Marvin L. White
Marvin L. White
President and Chief Executive Officer
Heather Boussios, Aptevo Therapeutics Inc.
[Signature Page to Request for Acceleration of Effectiveness of Registration Statement]